ASGCT 2021 View overview page

4:08
HSC gene editing: current approaches and remaining challenges
Valentina Vavassori • 27 May 2021
2:25
Enhancing AAV gene therapy in children with inborn errors of metabolism
Gloria Gonzalez-Aseguinolaza • 18 May 2021
1:35
Combining rAAV gene therapy with standard-of-care for the treatment of citrullinemia
Gloria Gonzalez-Aseguinolaza • 18 May 2021
2:08
Challenges in translating iPSC-based AMD therapies to the clinic
Masayo Takahashi • 26 May 2021
5:28
T cell and HSC gene editing for the treatment of Hyper-IgM Type 1
Valentina Vavassori • 27 May 2021
2:16
HSC gene editing highlights from ASGCT 2021
Valentina Vavassori • 27 May 2021
1:32
The potential of oncolytic adenoviral vectors
Margarita Romanenko • 13 May 2021
3:09
Vector-based therapies for metabolic disorders
Gloria Gonzalez-Aseguinolaza • 18 May 2021
4:17
miCAR: combining microRNA gene silencing with CAR expression
Marco Alessandrini • 20 May 2021
4:37
Developing CAR T-cell therapy for HIV
Marco Alessandrini • 20 May 2021
5:05
Hypoimmunogenic iPSCs: avoiding immune rejection
Sonja Schrepfer • 27 May 2021
2:01
Cardiosphere-derived cells in myocardial regeneration
Linda Marban • 19 May 2021
5:31
CRISPR-Cas9 gene-edited HSPCs for Friedreich’s ataxia
Stephanie Cherqui • 17 May 2021
4:10
Chemically modified mRNA encoding BMP-2 for bone healing
Christopher Evans • 19 May 2021
1:45
Neuraminidase could improve AAV9 gene therapy for Batten disease
Kathrin Meyer • 18 May 2021
1:58
Highlights from ASGCT 2021: iPSCs & the immunological barrier
Sonja Schrepfer • 27 May 2021
The content of VJRegenMed is intended for healthcare professionals